Table 5.

Clinical trials of DNAzymes in cancer treatment.

mRNA target	DNAzyme	Patient type	Phase	Trial size	Transfection reagent	Dose regime	Reference
c-jun	Dz13	BCC	1	9	DOTAP/DOPE	Three dose groups (10, 30, and 100 μg of Dz13) with three patients per group. Single intratumoral administration of 50 μL of Dz13 over four weeks	[63]
EBV-LMP	DZ1	NPC	1	40	Saline	Administration into the tumor under the local anesthetization via an epical endoscope at a dose of 6 mg of DZ1 + 0.1 mL of saline per injection twice weekly over seven weeks	[124]